Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2009.11.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aim: The aim of the study is to determine the effect of anti-inflammatory biological drugs (adalimumab, infliximab and rituximab) on the cardiovascular system during the treatment of patients with rheumatoid arthritis.
Methods: Involved in research 70 women aged 18 to 60 years with a confirmed diagnosis of rheumatoid arthritis (diagnosis confirmed by the American College of Rheumatology 2010 (ACR) and European League of Rheumatology (EULAR) classification criteria). Patients on standard treatment and biological drugs were divided into 3 groups, and the third group was divided into two subgroups.
Comparative Analysis of 2 Commercially Available Assays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Ther Drug Monit
January 2025
Department of Immunology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; and.
Background: Tumor necrosis factor is a crucial proinflammatory cytokine in immune-mediated diseases. Tumor necrosis factor inhibitors (TNFi), such as infliximab and adalimumab, effectively treat rheumatological and digestive disorders. However, challenges such as primary nonresponse, secondary treatment failure, or adverse reactions limit their efficacy.
View Article and Find Full Text PDF"Small is beautiful" - Examining reliable determination of low-abundant therapeutic antibody glycovariants.
J Pharm Anal
October 2024
Department of Biosciences and Medical Biology, Bioanalytical Research Labs, University of Salzburg, Salzburg, 5020, Austria.
Glycans associated with biopharmaceutical drugs play crucial roles in drug safety and efficacy, and therefore, their reliable detection and quantification is essential. Our study introduces a multi-level quantification approach for glycosylation analysis in monoclonal antibodies (mAbs), focusing on minor abundant glycovariants. Mass spectrometric data is evaluated mainly employing open-source software tools.
View Article and Find Full Text PDFAssessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab".
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease.
J Crohns Colitis
January 2025
Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON L8S 4K1, Canada.
Introduction: In inflammatory bowel disease (IBD), the number of eosinophils increases in the lamina propria of the intestinal tract, but their specific patho-mechanistic role remains unclear. Elevated blood eosinophil counts in active IBD suggest their potential as biomarkers for predicting response to biological therapies. This study evaluates blood eosinophil count trends and their predictive value for clinical response and endoscopic improvement in patients with IBD receiving ustekinumab or adalimumab induction therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!